Minimum effective doses of haloperidol for the treatment of first psychotic episode: A comparative study with risperidone and olanzapine

International Journal of Neuropsychopharmacology

Volumn 6, Issue 4, 2003, Pages 403-408

  Apiquian, Rogelio ^a   Fresán, Ana ^a   Herrera, Karen ^a   Ulloa, Rosa Elena ^b   Lóyzaga, Cristina ^a   De La Fuente Sandoval, Camilo ^a   Gutiérrez, Doris ^a   Nicolini, Humberto ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b Child Psychiat Hosp 'J N N'   (Mexico)

Author keywords

Antipsychotic treatment; First psychotic episode; Minimum doses

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; MALE; NEGATIVE SYNDROME; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; MEXICO; NEUROLOGIC EXAMINATION; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0742288279     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003742     Document Type: Article

References (22)

1. Addington D, Addington J, Maticka-Tyndale E (1993). Assessing depression in schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry 22S, 39-44.
2. Apiquian R, Páez F, Loyzaga C, Cruz E, Gutiérrez D, Suárez J, Ulloa RE, Fresán A, Vallejo G, Nicolini H, Medina-Mora ME (1997). Mexican study on the first psychotic episode: preliminary results, socidemographic and clinical characteristics. Salud Mental 20, 1-7.
3. Apiquian R, Ulloa RE, Páez F, Nicolini H (2002). The Mexican first-episode psychotic study: clinical characteristics and premorbid adjustment. Schizophrenia Research 53, 161-163.
4. Baldessarini RJ, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45, 79-91.
5. Barnes T (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
6. Barnes T, Joyce E (2001). Antipsychotic drug treatment: recent advances. Current Opinion in Psychiatry 14, 25-37.
7. DiMascio A, Bernardo D, Greenblat D, Marder J (1976). A controlled trial of amantadine in drug-induced extrapyramidal disorders. Archives of General Psychiatry 33, 599-602.
8. Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371-1376.
9. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R (1996). High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry 153, 948-950.
10. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 158, 360-369.
11. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS (1990). The Positive and Negative Syndrome Scale - Spanish adaptation. Journal of Nervous and Mental Disease 178, 510-517.
12. Keshavan MS, Schooler NR, Sweeney JA, Haas GL, Pettegrew JW (1998). Research and treatment strategies in first-episode psychoses: the Pittsburgh experience. British Journal of Psychiatry 172, 60-65.
13. Kopala LC, Good KP, Honer WG (1997). Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Journal of Clinical Psychopharmacology 17, 308-331.
14. Licht RW (1998). Olanzapine for primary negative symptoms. American Journal of Psychiatry 155, 1133-1134.
15. McEvoy JP, Hogarty GE, Steingard S (1991). Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higer haloperidol dose. Archives of General Psychiatry 48, 739-745.
16. National Institute of Mental Health (1975). Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercomunication 4, 3-6.
17. Oosthuizen P, Emsley RA, Turner J, Keyter N, Mail E (2001). Determining the optimal dose of haloperidol in first-episode psychosis. Journal of Psychopharmacology 15, 251-255.
18. Remington G, Chong SA, Kapur S (1999). Distinguishing change in primary and secondary negative symptoms. American Journal of Psychiatry 156, 974-975.
19. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley Jr. C, Tollefson GD (1999). Olanzapine versus haloperidol treatment in first-episode psychosis. American Journal of Psychiatry 156, 79-87.
20. Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S (2001). Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clinical Therapeutics 23, 942-956.
21. Wing J, Babor T, Brugh A, Bruke J, Cooper J, Gieel R, Jablenski A, Reiger D, Sartorius N (1990). SCAN Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 589-593.
22. Wirshing WC, Erhart SM, Pierre JM, Boyd JA (2000). Nonextrapyramidal side effects of novel antipsychotics. Current Opinion in Psychiatry 13, 45-50.